Aclaris Therapeutics Touts ATI-052 Potential for 3-Month Dosing, More Phase 1 Data Incoming [Yahoo! Finance]
Aclaris Therapeutics, Inc. (ACRS)
Last aclaris therapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
aclaristx.com
Company Research
Source: Yahoo! Finance
and will report two–three additional cohorts later this month while running phase 1b studies in severe atopic dermatitis and asthma with a phase 2b asthma study planned around year-end/turn of the year. ATI-052 is a TSLP and IL-4R bispecific that the company claims is ~70x more potent than tezepelumab and ~4x more potent than the combination of dupilumab plus tezepelumab in their testing, with healthy-volunteer PD readouts showing near-complete inhibition of TSLP and downstream IL-4/IL-13 activity. Safety signals to date include no conjunctivitis in SAD/MAD healthy volunteers and phase 1b AD readouts expected by year-end; Aclaris is also advancing small molecules such as ATI-2138 (dual ITK/JAK3) targeting alopecia, lichen planus and related indications. Interested in Aclaris Therapeutics, Inc.? Here are five stocks we like better. 3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices Aclaris Therapeutics (NASDAQ:ACRS) used an H.C. Wainwright inflammatory skin diseas
Show less
Read more
Impact Snapshot
Event Time:
ACRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACRS alerts
High impacting Aclaris Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ACRS
News
- Aclaris Therapeutics (ACRS) was given a new $10.00 price target by UBS Group AG.MarketBeat
- Aclaris Therapeutics (ACRS) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating on the stock.MarketBeat
- Aclaris Therapeutics (ACRS) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=ACRS&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "hMarketBeat
- Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual ConferenceGlobeNewswire
- Aclaris Therapeutics (ACRS) had its "outperform" rating reaffirmed by Wedbush. They now have a $8.00 price target on the stock.MarketBeat
ACRS
Earnings
- 2/26/26 - Miss
ACRS
Sec Filings
- 4/7/26 - Form SCHEDULE
- 3/26/26 - Form SCHEDULE
- 3/17/26 - Form SCHEDULE
- ACRS's page on the SEC website